<DOC>
	<DOCNO>NCT02480439</DOCNO>
	<brief_summary>The purpose study assess relative bioavailability TAK-648 tablet compare TAK-648 oral solution , assess effect food bioavailability TAK-648 tablet healthy participant .</brief_summary>
	<brief_title>A Study Assess Relative Bioavailability Assess Effect Food Bioavailability TAK-648 Tablet Healthy Participants</brief_title>
	<detailed_description>This study assess relative Bioavailability ( BA ) TAK-648 tablet compare TAK-648 solution effect food BA TAK-648 tablet . The study enroll approximately 24 healthy participant . Participants randomly assign one three treatment sequence : - TAK-648 tablet fed state , follow TAK-648 tablet fast state , follow TAK-648 oral solution fast state - TAK-648 tablet fast state , follow TAK-648 oral solution fast state , follow TAK-648 tablet fed state - TAK-648 oral solution fast state , TAK-648 tablet fed state , TAK-648 tablet fast state The dosing period subsequent period separate minimum 7-day washout interval . Participants ask take single dose TAK-648 tablet oral solution Day 1 period . This single-center trial conduct United States . Participants make 4 visit clinic include three 4-day period confinement clinic , contact telephone 30 day last dose study drug follow-up assessment .</detailed_description>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>1 . Healthy male female age 18 55 year , inclusive , time informed consent first study medication dose . 2 . Weighs least 50 kilogram ( kg ) ( 110 pound [ lbs ] ) body mass index ( BMI ) 18.0 30.0 kilogram per square meter ( kg/m^2 ) , inclusive Screening . 3 . Has systolic blood pressure great ( &gt; ) 90 less equal ( &lt; = ) 150 millimeter mercury ( mmHg ) diastolic blood pressure &gt; 60 &lt; =90 mm Hg Screening Checkin ( Day 1 ) Period 1 . If range , may repeat eligibility determination within maximum 5 minute . 4 . Has calculate creatinine clearance &gt; 60 milliliter per minute ( mL/min ) Screening Checkin ( Day 1 ) Period 1 . 5 . Male participant nonsterilized sexually active female partner childbearing potential agrees use adequate contraception signing inform consent throughout duration study 12 week last dose . 6 . Female participant childbearing potential sexually active nonsterilized male partner agree use routinely adequate contraception signing inform consent throughout duration study 12 week last dose . 1 . Has receive investigational compound within 30 day prior first dose study medication . 2 . Has receive TAK648 previous clinical study therapeutic agent . 3 . Is immediate family member , study site employee , dependent relationship study site employee involve conduct study ( example , spouse , parent , child , sibling ) may consent duress . 4 . Has significant medical history currently uncontrolled clinical condition , may render unsafe participant participate study , may impact ability participant participate study , may potentially confound study result . 5 . Has history significant gastrointestinal ( GI ) disorder manifest persistent , chronic , intermittent nausea , vomit , diarrhea , current recent ( within 6 month ) GI disease would influence absorption drug . 6 . Has diagnosis major depression , bipolar disorder , anxiety disorder , receive medication treat psychological disorder within 1 year . 7 . Has risk suicide accord investigator 's clinical judgment per ColumbiaSuicide Severity Rating Scale ( CSSRS ) screen make suicide attempt past 6 month prior screen . 8 . Has know hypersensitivity component formulation TAK648 , phosphodiesterase type 4 ( PDE4 ) inhibitor ( example , roflumilast ) . 9 . Has take exclude medication , supplement , food product time period list Prohibited Medications table . 10 . Has abnormal Screening Checkin ( Day 1 ) Period 1 laboratory value suggest clinically significant underlying disease participant follow laboratory abnormality : Alanine aminotransferase ( ALT ) and/or aspartate aminotransferase ( AST ) &gt; 2.5* upper limit normal ( ULN ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Drug Therapy</keyword>
</DOC>